LK – Speaker or advisor: Amgen, Astellas, Dendreon, Ferring, GSK, Janssen, Profound Medical, and Sanofi Aventis; AB – Nothing to disclose; AdlT – Consultant or advisor: Astellas, Ferring, Ipsen, Takeda, and PFM; JN – Consultant or advisor: Boehringer Ingelheim, Probi AB.
Writing assistance provided by Dr Tabasum Mughal.
Ferring Pharmaceuticals sponsored this symposium. The views and opinions expressed are those of the authors.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
This symposium was focused on reviewing androgen deprivation therapy (ADT) in prostate cancer, highlighting the implications of this therapy in clinical practice and including a focus on the cardiovascular (CV) risk associated with ADT therapy.
Please view the full content in the pdf above.
